company background image
CLDX

Celldex TherapeuticsNasdaqCM:CLDX Stock Report

Market Cap

US$1.7b

7D

-9.9%

1Y

81.9%

Updated

04 Dec, 2021

Data

Company Financials +
CLDX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CLDX Stock Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.

Celldex Therapeutics Competitors

Emergent BioSolutions

NYSE:EBS

US$2.3b

Chimerix

NasdaqGM:CMRX

US$490.8m

Bavarian Nordic

CPSE:BAVA

kr.19.3b

Price History & Performance

Summary of all time highs, changes and price drops for Celldex Therapeutics
Historical stock prices
Current Share PriceUS$35.68
52 Week HighUS$57.20
52 Week LowUS$15.37
Beta2.74
1 Month Change-25.47%
3 Month Change-34.21%
1 Year Change81.95%
3 Year Change819.11%
5 Year Change-36.57%
Change since IPO-68.83%

Recent News & Updates

Sep 23

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

21st Century advances on 20th century genetic technologies have opened Celldex Therapeutics Inc.’s developments aimed specifically at induced weaknesses. At this point of the market they also outdo the prospects of many stocks widely-held by Seeking Alpha readers, contributors, and commenters. This is an article about stock prices more than about healthcare technologies, which have been extensively considered by those with appropriate expertise. For investment in portfolios where wealth-building is a principal objective, evolving economics now make biotech industry stocks leading candidates.

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Celldex...

Shareholder Returns

CLDXUS BiotechsUS Market
7D-9.9%-4.1%-2.7%
1Y81.9%-1.4%16.6%

Return vs Industry: CLDX exceeded the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: CLDX exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is CLDX's price volatile compared to industry and market?
CLDX volatility
CLDX Average Weekly Movement6.3%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: CLDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CLDX's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983124Anthony Maruccihttps://www.celldex.com

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company’s clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company’s proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

Celldex Therapeutics Fundamentals Summary

How do Celldex Therapeutics's earnings and revenue compare to its market cap?
CLDX fundamental statistics
Market CapUS$1.66b
Earnings (TTM)-US$72.26m
Revenue (TTM)US$8.10m

205.5x

P/S Ratio

-23.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLDX income statement (TTM)
RevenueUS$8.10m
Cost of RevenueUS$49.06m
Gross Profit-US$40.96m
ExpensesUS$31.31m
Earnings-US$72.26m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.55
Gross Margin-505.50%
Net Profit Margin-891.92%
Debt/Equity Ratio0%

How did CLDX perform over the long term?

See historical performance and comparison

Valuation

Is Celldex Therapeutics undervalued compared to its fair value and its price relative to the market?

3.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CLDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CLDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLDX is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Celldex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-19.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLDX's revenue is expected to decline over the next 3 years (-26.5% per year).

High Growth Revenue: CLDX's revenue is forecast to decline over the next 3 years (-26.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLDX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Celldex Therapeutics performed over the past 5 years?

21.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLDX is currently unprofitable.

Growing Profit Margin: CLDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLDX is unprofitable, but has reduced losses over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare CLDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: CLDX has a negative Return on Equity (-16.55%), as it is currently unprofitable.


Financial Health

How is Celldex Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CLDX's short term assets ($426.6M) exceed its short term liabilities ($14.2M).

Long Term Liabilities: CLDX's short term assets ($426.6M) exceed its long term liabilities ($9.3M).


Debt to Equity History and Analysis

Debt Level: CLDX is debt free.

Reducing Debt: CLDX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLDX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CLDX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 18.1% each year


Dividend

What is Celldex Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Anthony Marucci (59 yo)

13.25yrs

Tenure

US$3,006,668

Compensation

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...


CEO Compensation Analysis

Compensation vs Market: Anthony's total compensation ($USD3.01M) is about average for companies of similar size in the US market ($USD3.72M).

Compensation vs Earnings: Anthony's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CLDX's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: CLDX's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.


Top Shareholders

Company Information

Celldex Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Celldex Therapeutics, Inc.
  • Ticker: CLDX
  • Exchange: NasdaqCM
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.665b
  • Shares outstanding: 46.66m
  • Website: https://www.celldex.com

Number of Employees


Location

  • Celldex Therapeutics, Inc.
  • Perryville III Building
  • Suite 220
  • Hampton
  • New Jersey
  • 8827
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:06
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.